InARush

@tradingsssss Long term

@Rushing9000 Depends how long you want to hold

$CRVS i think most of the AD companies are going on a run bc of that $APGE acquisition

@RudyResearch What is your price target for $CCCC in 2-3 years?

$abvx is now a bond, sells for at least 170+ seems pretty certain along with $prax approval. $cccc $cue and $zura for multi baggers now.

@cr0upier @dragonballchad @A_May_MD What if they get a delta above 25m

@dragonballchad $40 - $50 seems reasonable. @A_May_MD believes it's a 10x on successful P3 readout.

$Tenx whats the expected upside here if ph3 hits considering their heavy dilution and cash need? goes up to 40?

@pmill145 @semodough Exactly, KOL acting as if it’s the first time an oral medication that has bid dosing or food effects has blockbuster potential.

@semodough ? As if most things you put in your mouth don't require being aware of whether it needs to be taken with food or without, or time of day/night?

$CRVS $KYMR Cowen KOL KOLs Expect Oral/Injectable Use Could Eventually Split The 30 Billion AD Market Multiple oral agents are in development for AD, and our KOL believes treatment selection between oral and injectables could be dictated by patient preference - especially if oral agents achieve similar efficacy to injectable agents. He expects that most patients might prefer orals initially, especially compared to currently available frequently injected agents - leading to his expectation for 70% oral / 30% injectable split in utilization. However, given compliance issues with oral agents and the availability of long-acting agents he expects the split will eventually be closer to 50/50. If oral drugs demonstrate a food effect requiring specific timing with dosing, then some patient preference might switch towards injectable options.

@A_May_MD What’s next? Are we running it back with $pali?

$ABVX closing like the offering is coming. Sharpen your knives 🫡

@STvrosb Will it cross 16?

$CRVS Momentum for CRVS is strongly bullish. The 14-period Slow Stochastic oscillator is above 80! This means that investors have been actively purchasing shares & driving the price higher.

@DamaskCapital Don’t disagree with you. Think there’s room for multiple players in AD even with all the competition. I do think safety validation over time will result in an increased likelihood of closing the gap vs other competitors.

It's a novel ITK inhibition mechanism, which is always going to be met with some caution at first, even if preclinical safety data is v strong. Prescribers likely will want more real world safety data before prescribing in 1L. Likewise, there's going to be so much existing competition in AD ($KYMR, $NKTR, generic Dupi, et al) at launch; seems far more realistic to underwrite 20%+ in 2L than tangible market share in 1L, at least for now. But who knows, on paper it definitely fits the efficacy benchmarks for 1L in my view.

Someone tell me why $CRVS isn't strong R/R at these levels (<$15/sh). Yes, they'll likely be 2L only in AD, but that's still a 3bn+ dollar opportunity, and at least 1bn risk-adjusted in the US alone. Rare that a biotech with data this promising trades at/below 1x risk-adjusted peak sales. Thoughts @A_May_MD @seedy19tron ?

@HOThomasWPhelps @fortunoaurelar Since the partnership between $GLUE and $NVS was announced, the value of $GLUE has risen 367%. A partnership would be great news as well for shareholders.

Not commenting on timing or what stage anything would happen, but NVS were not as high on my list until I did work on it over the weekend. When the time is right we will hear about something, but CRVS has lots of data coming and I would not think is in a rush. I would think $NVS is aware and watching, especially as they are partnered w/ $GLUE on their VAV1 degrader for Th17 diseases and I have written about the close proximity of VAV1 and ITK in TCR signaling and their differences. If you are interested in VAV1, you would have to know about ITK.

$NVS website on R&D - Novartis interests seems good fit w/ $CRVS #soquelitinib oral ITK inhibitor: oncology and I&I Soquelitinib: - oral small molecule - immuno-derm (AD, HS) - durable profile = NVS goal long-term remission w/o chronic immune suppression novartis.com/research-and-d…

@HOThomasWPhelps If it is $CRVS, think it’ll be a partnership rather than a buyout. Think miller would like to more value creation.

Prior post: I showed similarities and differences in $GLUE #VAV1 (scaffold protein) target in Tcells v $CRVS #ITK (kinase) target $NVS already in space, partnered ww/ $GLUE and should be aware of the pathway proximity of the two and their differences x.com/HOThomasWPhelp…

@GhostCat_ @teslarosa I don’t know if $CRVS would be selling off this early but I do think a partnership could occur this early/

@teslarosa Think $crvs provides the best r/r for them at this point and mgmt probably more inclined to sell

Monitoring the chains of all these companies for a potential $NVS acquisition. 1. $CVTK Good target, bit expensive 2. $CRVS Phase 1 a little too early, but cheap. 3. $NKTR Not super confident it would be them, but do it anyways Novartis!

@tejada444 @JoseRestonVA @ASchulz888 @jayabacus $CRVS should be their answer.

Won’t Zumi and all the IL4/13’s face bisimilar’s in 2032 (ish) for 1L? Why wouldn’t insurance simply mandate a biosimilar first? There must be something or why would they spend $11B to buy APGE?

@HOThomasWPhelps Do you think $CRVS could also enroll early? I’m hoping they can, but since they are enrolling 40% r/r patients I think it may take longer.

Atopic Dermatitis Space Heating Up? Plausible $KYMR accelerating oral #STAT6 degrader KT-621 timeline increased competitive urgency around $APGE for $ABBV buyout this week Today's news compresses lead $APGE and $NKTR biologics had over orals in development behind them

@Investorclimber @HOThomasWPhelps I am $CRVS long. One argument that I’ve heard is that due to KYMR having a target where safety is already known.

@HOThomasWPhelps As I consider you wise, any idea on why the different behaviour of the market on the different tickers?

$KYMR up 24% this morning adding over $2 billion to its market cap after enroling its Ph2b atopic dermatitis months ahead of schedule $KYMR

@Investorclimber I think $CRVS can do the same.

@Rushing9000 6-7 months.

$KYMR completes enrollment. I guess it will be up today around 50% and $NKTR or $CRVS deserve to be down 30-40%. Isn't this how AtD stocks work?

@haodongvli Is this a ten year play

$CRVS: please do not sell yourself cheap $APGE

@pmill145 @biotech_jack I think it’s possible to go back up to $13-14 range

@biotech_jack No clue but one thing's for sure- the many $crvs shorts caught flat-footed.

How much could $CRVS rise on Monday due to the $APGE deal? Please provide estimates.

@Ikkydiphoenix I think it’s probably not the latter

$APGE BO tells us a thing about $NKTR and $CRVS: or $ABBV didn't consider them or they want more than $11B